Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis

Results from a phase 3 tofacitinib program

Sonja Ständer, Thomas A. Luger, Joseph C. Cappelleri, Andrew G. Bushmakin, Carla Mamolo, Michael A. Zielinski, Anna M. Tallman, Gil Yosipovitch

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis, and review the effect of tofacitinib on pruritus in patients with psoriasis participating in Phase 3 studies (N = 3,641). The ISI showed high test–retest reliability (intra-class correlation coefficient: 0.84). The clinically important difference was defined as a 1.48-point change, using Patient Global Assessment as an anchor. Mean changes from baseline in ISI scores with tofacitinib were significantly greater than placebo by Day 2 and exceeded the clinically important difference by Week 4 and Week 2 for tofacitinib 5 and 10 mg twice daily, respectively. The sound psychometric properties of the ISI as an assessment tool for pruritus in psoriasis were confirmed. Tofacitinib provided clinically meaningful improvements in psoriatic pruritus versus placebo.

Original languageEnglish (US)
Pages (from-to)340-345
Number of pages6
JournalActa Dermato-Venereologica
Volume98
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Pruritus
Psoriasis
Psychometrics
Placebos
Janus Kinases
tofacitinib

Keywords

  • Clinically important difference
  • Itch severity item
  • Patient global assessment
  • Pruritus
  • Psoriasis
  • Tofacitinib

ASJC Scopus subject areas

  • Dermatology

Cite this

Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis : Results from a phase 3 tofacitinib program. / Ständer, Sonja; Luger, Thomas A.; Cappelleri, Joseph C.; Bushmakin, Andrew G.; Mamolo, Carla; Zielinski, Michael A.; Tallman, Anna M.; Yosipovitch, Gil.

In: Acta Dermato-Venereologica, Vol. 98, No. 3, 01.01.2018, p. 340-345.

Research output: Contribution to journalArticle

Ständer, Sonja ; Luger, Thomas A. ; Cappelleri, Joseph C. ; Bushmakin, Andrew G. ; Mamolo, Carla ; Zielinski, Michael A. ; Tallman, Anna M. ; Yosipovitch, Gil. / Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis : Results from a phase 3 tofacitinib program. In: Acta Dermato-Venereologica. 2018 ; Vol. 98, No. 3. pp. 340-345.
@article{62570c19eaba4f0c88fc3832095f84a3,
title = "Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis: Results from a phase 3 tofacitinib program",
abstract = "Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis, and review the effect of tofacitinib on pruritus in patients with psoriasis participating in Phase 3 studies (N = 3,641). The ISI showed high test–retest reliability (intra-class correlation coefficient: 0.84). The clinically important difference was defined as a 1.48-point change, using Patient Global Assessment as an anchor. Mean changes from baseline in ISI scores with tofacitinib were significantly greater than placebo by Day 2 and exceeded the clinically important difference by Week 4 and Week 2 for tofacitinib 5 and 10 mg twice daily, respectively. The sound psychometric properties of the ISI as an assessment tool for pruritus in psoriasis were confirmed. Tofacitinib provided clinically meaningful improvements in psoriatic pruritus versus placebo.",
keywords = "Clinically important difference, Itch severity item, Patient global assessment, Pruritus, Psoriasis, Tofacitinib",
author = "Sonja St{\"a}nder and Luger, {Thomas A.} and Cappelleri, {Joseph C.} and Bushmakin, {Andrew G.} and Carla Mamolo and Zielinski, {Michael A.} and Tallman, {Anna M.} and Gil Yosipovitch",
year = "2018",
month = "1",
day = "1",
doi = "10.2340/00015555-2856",
language = "English (US)",
volume = "98",
pages = "340--345",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "3",

}

TY - JOUR

T1 - Validation of the itch severity item as a measurement tool for pruritus in patients with psoriasis

T2 - Results from a phase 3 tofacitinib program

AU - Ständer, Sonja

AU - Luger, Thomas A.

AU - Cappelleri, Joseph C.

AU - Bushmakin, Andrew G.

AU - Mamolo, Carla

AU - Zielinski, Michael A.

AU - Tallman, Anna M.

AU - Yosipovitch, Gil

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis, and review the effect of tofacitinib on pruritus in patients with psoriasis participating in Phase 3 studies (N = 3,641). The ISI showed high test–retest reliability (intra-class correlation coefficient: 0.84). The clinically important difference was defined as a 1.48-point change, using Patient Global Assessment as an anchor. Mean changes from baseline in ISI scores with tofacitinib were significantly greater than placebo by Day 2 and exceeded the clinically important difference by Week 4 and Week 2 for tofacitinib 5 and 10 mg twice daily, respectively. The sound psychometric properties of the ISI as an assessment tool for pruritus in psoriasis were confirmed. Tofacitinib provided clinically meaningful improvements in psoriatic pruritus versus placebo.

AB - Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis, and review the effect of tofacitinib on pruritus in patients with psoriasis participating in Phase 3 studies (N = 3,641). The ISI showed high test–retest reliability (intra-class correlation coefficient: 0.84). The clinically important difference was defined as a 1.48-point change, using Patient Global Assessment as an anchor. Mean changes from baseline in ISI scores with tofacitinib were significantly greater than placebo by Day 2 and exceeded the clinically important difference by Week 4 and Week 2 for tofacitinib 5 and 10 mg twice daily, respectively. The sound psychometric properties of the ISI as an assessment tool for pruritus in psoriasis were confirmed. Tofacitinib provided clinically meaningful improvements in psoriatic pruritus versus placebo.

KW - Clinically important difference

KW - Itch severity item

KW - Patient global assessment

KW - Pruritus

KW - Psoriasis

KW - Tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=85043339333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043339333&partnerID=8YFLogxK

U2 - 10.2340/00015555-2856

DO - 10.2340/00015555-2856

M3 - Article

VL - 98

SP - 340

EP - 345

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 3

ER -